Replimune Group, Inc. (NASDAQ:REPL) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Replimune Group, Inc. (NASDAQ:REPL) have earned a consensus recommendation of “Moderate Buy” from the eleven brokerages that are presently covering the company, MarketBeat.com reports. Two analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation, six have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $9.75.

A number of research firms have issued reports on REPL. Wedbush raised shares of Replimune Group from a “neutral” rating to an “outperform” rating and raised their price target for the stock from $4.00 to $18.00 in a research report on Monday, October 20th. Leerink Partnrs upgraded shares of Replimune Group from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 20th. HC Wainwright raised shares of Replimune Group from a “neutral” rating to a “buy” rating and set a $12.00 price target on the stock in a report on Monday, October 27th. JPMorgan Chase & Co. upgraded Replimune Group from an “underweight” rating to a “neutral” rating and set a $11.00 price objective for the company in a research note on Monday, October 20th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Replimune Group in a research note on Monday, December 15th.

Replimune Group Stock Performance

Shares of REPL opened at $9.88 on Wednesday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 6.31 and a current ratio of 6.31. The stock has a 50-day moving average of $8.97 and a two-hundred day moving average of $7.63. The stock has a market cap of $774.99 million, a P/E ratio of -2.86 and a beta of 0.66. Replimune Group has a one year low of $2.68 and a one year high of $14.80.

Replimune Group (NASDAQ:REPL) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.03). As a group, research analysts predict that Replimune Group will post -2.97 EPS for the current year.

Insider Buying and Selling

In other Replimune Group news, CEO Sushil Patel sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, December 2nd. The stock was sold at an average price of $11.13, for a total value of $111,300.00. Following the sale, the chief executive officer owned 333,576 shares in the company, valued at approximately $3,712,700.88. This represents a 2.91% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Kapil Dhingra sold 3,169 shares of the business’s stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $10.40, for a total transaction of $32,957.60. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 25,625 shares of company stock valued at $257,607. Insiders own 5.20% of the company’s stock.

Institutional Investors Weigh In On Replimune Group

Institutional investors have recently modified their holdings of the business. Tudor Investment Corp ET AL purchased a new position in Replimune Group during the third quarter worth approximately $87,000. Scientech Research LLC acquired a new position in shares of Replimune Group during the 3rd quarter worth approximately $102,000. Fcpm Iii Services B.V. raised its stake in shares of Replimune Group by 6.4% during the 3rd quarter. Fcpm Iii Services B.V. now owns 4,158,368 shares of the company’s stock worth $17,424,000 after buying an additional 248,672 shares during the period. Braidwell LP lifted its position in shares of Replimune Group by 550.3% during the 3rd quarter. Braidwell LP now owns 2,750,092 shares of the company’s stock valued at $11,523,000 after buying an additional 2,327,205 shares in the last quarter. Finally, Alliancebernstein L.P. grew its stake in Replimune Group by 23.4% in the 3rd quarter. Alliancebernstein L.P. now owns 63,540 shares of the company’s stock valued at $266,000 after acquiring an additional 12,050 shares during the period. 92.53% of the stock is currently owned by institutional investors and hedge funds.

About Replimune Group

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.